Better Context → Better Decisions
Context counts in life sciences. The Celltelligence analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access can use our library to search all of the content already delivered to their inbox. If you think a colleague would enjoy receiving our content, reach out to the Celltelligence team to make it happen.
Free
Posted in: Autologous, CAR-T, CD19 Feb 01 | 2024Kymriah Sales Continue to Decline; No Updates on Cell Therapy Programs; Novartis’s Q4 2023 Earnings Call SummaryAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Jan 31 | 2024Breyanzi Regulatory Applications for R/R FL and R/R MCL Accepted in the US and JapanAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T, CD19, Dual/triple agonist Jan 30 | 2024Gracell’s GC012F Receives IND Clearance in Early Line MMAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T Jan 26 | 2024CHMP Adopts Positive Opinion for Abecma in ≥3L MM; January CHMP HighlightsAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T Jan 24 | 2024Sales of Carvykti Continue to Grow; FDA and EMA Advisory Committees Will Review Carvykti Applications for Early MM; JNJ Considers Entering in Autoimmune Diseases; JNJ’s Q4 2023 Earnings Call SummaryAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Jan 22 | 2024Obe-cel BLA in R/R B-ALL Accepted Although No Priority Review Was GrantedAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T Jan 22 | 2024Could Abecma Receive a CHMP Positive Opinion on Friday?; January’s CHMP AgendaAccess Free BlastFree
Posted in: Allogeneic, Autologous, CAR-T, CD19, TCR Jan 12 | 2024JPM 2024 Analysis Day 4: Adaptimmune and CaribouAccess Free BlastFree
Posted in: Allogeneic, Autologous, CAR-T, CD19 Jan 12 | 2024JPM 2024 Analysis Days 2 & 3: Imugene, CRISPR Tx, and PrecigenAccess Free BlastFree
Posted in: Allogeneic, CAR-T, CD19 Jan 11 | 2024JPM 2024 Analysis Day 3: AllogeneAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T Jan 10 | 2024JPM 2024 Analysis Day 2: Legend, AstraZeneca, and BioNTechAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T, CD19, Dual/triple agonist Jan 09 | 2024JPM 2024 Analysis Day 1: BMS, Gilead, Novartis, and JNJAccess Free BlastFree
Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD19 Jan 05 | 2024Poseida Publishes Future Milestones for 2024; Company Considering Entrance in Autoimmune Diseases; Adaptimmune to Pursue Lete-cel Approval By 2026Access Free BlastFree
Posted in: Autologous, BCMA, CAR-T, CD19 Jan 05 | 2024We’re Back! Holiday Recap Ahead of JPM 2024 (Blast 2/2): Risk of Secondary Hematological Malignancies Included in the Black Box of Carvykti’s US Prescribing Information; FDA Approved Yescarta’s Label Update to Incorporate OS Data; Galapagos Initiates Recruitment of GLPG5301 Trial in ≥3L MMAccess Free BlastFree
Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD19 Jan 04 | 2024We’re Back! Holiday Recap Ahead of JPM 2024 (Blast 1/2): Thoughts on AstraZeneca’s Acquisition of GracellAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T, CD19 Dec 15 | 2023Could Abecma and Carvykti Be Approved in January 2024? Obe-cel MAA Could Happen in Q1 2024; December CHMP HighlightsAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T Dec 14 | 2023Uncertainty around OS Benefit Induced by Abecma in 3 – 5L MM; A MAIC Analysis Supports Carvykti’s Superiority versus Abecma in Early Line MM; ASH 2023 Analysis 7Access Free BlastFree
Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD19 Dec 14 | 2023Anito-cel Elicits Improved Responses Across HR Subgroups; Gracell’s GC012F Shows Best-In-Class Safety and Efficacy Profiles; Increased Lymphodepleting Dose Enhances P-BCMA-ALLO1's Responses Significantly; ASH 2023 Analysis 6Access Free BlastFree
Posted in: Allogeneic, CAR-T, CD19 Dec 14 | 2023A New Pivotal Trial for Caribou’s CB-010 in ≥2L LBCL to Start in 2024; Is the FDA Changing Perspective on the Clinical Development of Allogeneic CAR-Ts in Earlier Lines?Access Free BlastFree
Posted in: Autologous, CD19 Dec 13 | 2023JNJ / AbelZeta and Mustang Bio Present Clinical Updates from their Assets Targeting CD20 in NHL; ASH 2023 Analysis 5Access Free BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.